Các bài viết có thể truy cập công khai - David P CarboneTìm hiểu thêm
Tổng thểNIHNSFCDoDCancer Research UKNSFNHMRCLung Cancer Research Foundation, USADOESNSFVAFWFFWODFGAcademy of FinlandNIHRWellcomeEuropean CommissionGovernment of SpainGovernment of ItalyAutism Speaks Inc, USALUNGevity Foundation, USAAIRC Foundation for Cancer Research in ItalyDamon Runyon Cancer Research Foundation
Không có ở bất kỳ nơi nào: 4
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non–small cell lung cancer
R Mutter, B Lu, DP Carbone, I Csiki, L Moretti, DH Johnson, JD Morrow, ...
Clinical Cancer Research 15 (6), 2158-2165, 2009
Các cơ quan ủy nhiệm: US National Institutes of Health
Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer
Y Huang, DP Carbone
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1855 (2), 193-201, 2015
Các cơ quan ủy nhiệm: National Natural Science Foundation of China
Clinical and molecular correlates of tumor mutation burden in non-small cell lung cancer
MF Sharpnack, JH Cho, TS Johnson, GA Otterson, PG Shields, K Huang, ...
Lung Cancer 146, 36-41, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
SP141 Serum proteomics in lung cancer
D Carbone
European Journal of Cancer Supplements 7 (4), 1-2, 2009
Các cơ quan ủy nhiệm: Cancer Research UK
Có tại một số nơi: 138
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
Các cơ quan ủy nhiệm: US National Institutes of Health
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ...
Journal of clinical oncology 30 (8), 863-870, 2012
Các cơ quan ủy nhiệm: US National Institutes of Health
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ...
Journal of clinical oncology 33 (18), 2004-2012, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
Delivering affordable cancer care in high-income countries
R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ...
The lancet oncology 12 (10), 933-980, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health, Research Foundation (Flanders)
PDL1 Regulation by p53 via miR-34
MA Cortez, C Ivan, D Valdecanas, X Wang, HJ Peltier, Y Ye, L Araujo, ...
Journal of the National Cancer Institute 108 (1), djv303, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Adenosine receptors in regulation of dendritic cell differentiation and function
SV Novitskiy, S Ryzhov, R Zaynagetdinov, AE Goldstein, Y Huang, ...
Blood, The Journal of the American Society of Hematology 112 (5), 1822-1831, 2008
Các cơ quan ủy nhiệm: US National Institutes of Health
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ...
Journal of Clinical Oncology 35 (13), 1403-1410, 2017
Các cơ quan ủy nhiệm: US National Institutes of Health
Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ...
Journal of Thoracic Oncology 11 (5), 613-638, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II …
D Morgensztern, B Besse, L Greillier, R Santana-Davila, N Ready, ...
Clinical Cancer Research 25 (23), 6958-6966, 2019
Các cơ quan ủy nhiệm: US National Institutes of Health
Predictive markers for the efficacy of anti–PD-1/PD-L1 antibodies in lung cancer
T Shukuya, DP Carbone
Journal of thoracic oncology 11 (7), 976-988, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Current status and future perspectives on neoadjuvant therapy in lung cancer
GM Blumenthal, PA Bunn Jr, JE Chaft, CE McCoach, EA Perez, ...
Journal of Thoracic Oncology 13 (12), 1818-1831, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers
A Drilon, JJ Lin, T Filleron, A Ni, J Milia, I Bergagnini, V Hatzoglou, ...
Journal of Thoracic Oncology 13 (10), 1595-1601, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
Host A2B adenosine receptors promote carcinoma growth
S Ryzhov, SV Novitskiy, DP Carbone, I Biaggioni, R Zaynagetdinov, ...
Neoplasia 10 (9), 987-995, 2008
Các cơ quan ủy nhiệm: US National Institutes of Health
Non–small-cell lung cancer: role of the immune system and potential for immunotherapy
DP Carbone, DR Gandara, SJ Antonia, C Zielinski, L Paz-Ares
Journal of Thoracic Oncology 10 (7), 974-984, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ...
ESMO open 6 (5), 100273, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
JE Chaft, F Oezkan, MG Kris, PA Bunn, II Wistuba, DJ Kwiatkowski, ...
Nature medicine 28 (10), 2155-2161, 2022
Các cơ quan ủy nhiệm: US National Institutes of Health, German Research Foundation
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ